Diagnosing CMT and Understanding Your Tests
Last updated:
Diagnosing Charcot-Marie-Tooth (CMT) requires nerve conduction studies (NCS) and EMG tests to measure nerve damage, using a 38 m/s speed cutoff to distinguish between Type 1 and Type 2. However, genetic testing remains the gold standard to pinpoint the exact mutation and confirm the diagnosis.
Key Takeaways
- • Physical exams for CMT often look for high foot arches, hammer toes, and a loss of deep tendon reflexes.
- • Nerve Conduction Studies (NCS) and EMG tests measure the electrical activity and speed of your nerves to classify the type of damage.
- • A nerve conduction speed in the arm below 38 m/s usually indicates CMT Type 1, while a speed above 38 m/s points to CMT Type 2.
- • Genetic testing using a Next-Generation Sequencing (NGS) panel is the gold standard for confirming a CMT diagnosis and identifying the specific mutation.
- • It is critical to differentiate inherited CMT from CIDP, an autoimmune condition with similar symptoms that requires completely different medical treatments.
The journey to a Charcot-Marie-Tooth (CMT) diagnosis often begins with a physical exam where a doctor looks for classic signs like high foot arches (pes cavus), curled toes (hammer toes), or a loss of deep tendon reflexes [1][2][3]. However, to confirm the diagnosis and determine the specific type of CMT, specialized tests are required.
The Electrical Tests: EMG and NCS
To see how your nerves are functioning, doctors use two tests that measure the electrical activity in your muscles and nerves.
- Nerve Conduction Study (NCS): This test measures how fast and how strong an electrical signal travels through your nerves [3]. It involves placing small sensors on your skin and giving the nerve a tiny electrical pulse (which feels like a quick “tap” or “tingle”).
- Electromyography (EMG): This test checks the health of your muscles and the nerves that control them [3][4]. A very thin needle is inserted into the muscle to record its electrical activity while you relax and then gently contract the muscle.
The “38 m/s” Cutoff
In the world of CMT, the number 38 meters per second (m/s) is a critical marker when measuring the upper extremity motor nerves (like the median or ulnar nerve in the arm) [3][5]. (Leg nerves are naturally slower and often more degraded, so arm nerves are used for this classification).
- Below 38 m/s: This usually points toward CMT Type 1 (Demyelinating), where the “insulation” (myelin) is damaged, causing the signal to slow down [3][5].
- Above 38 m/s: This often points toward CMT Type 2 (Axonal), where the “wire” (axon) is damaged. In this case, the signal speed might be near normal, but the signal strength is often very low [3][6].
The Genetic “Gold Standard”
While electrical tests can tell you how the nerve is damaged, genetic testing is the only way to find out why [7][8]. Using a Next-Generation Sequencing (NGS) panel, doctors can look at over 100 known CMT genes at once [9][10]. This is the “gold standard” because it identifies the exact mutation, which is essential for understanding your personal prognosis and qualifying for future clinical trials [11][8].
Please note that waiting for genetic test results can take several weeks to a few months [7]. This delay is normal and does not mean anything is wrong with your sample.
CMT vs. CIDP: Why the Distinction Matters
It is vital to distinguish CMT from Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
- CIDP is an autoimmune condition where the body attacks the nerves. Unlike CMT, CIDP is often treatable with immunotherapy like steroids or IVIg [12][13].
- The Risk of Misdiagnosis: Because the symptoms look similar, some CMT patients are misdiagnosed with CIDP and given years of expensive, ineffective treatments [12][14].
Doctors look for specific “red flags” that suggest CIDP rather than CMT, such as asymmetric weakness (affecting one side more than the other) or a conduction block (where the electrical signal stops completely at one point) [12][15].
Your Completeness Checklist
Ensure the following information is documented in your medical record to support an accurate diagnosis:
-
[ ] Full Clinical History: Detailed notes on when symptoms started and any family history of foot issues [3].
-
[ ] NCS/EMG Report: Including specific conduction velocities (m/s) and signal amplitudes [3][16].
-
[ ] Genetic Testing Results: A copy of the laboratory report identifying the specific gene mutation [7][8].
-
[ ] Exclusion of Mimics: Documentation ruling out diabetes, B12 deficiency, and CIDP [7][12].
Frequently Asked Questions
What does the 38 m/s cutoff mean on my nerve conduction study?
Why do I need a genetic test for CMT if I already had an EMG?
What is a Next-Generation Sequencing (NGS) panel for CMT?
How is CMT different from CIDP?
Why does it take so long to get CMT genetic test results?
Questions for Your Doctor
- • What was the exact recorded speed (m/s) of my Nerve Conduction Velocity (NCV) test in my arm, and does it fall below the 38 m/s cutoff?
- • Did my electrophysiology report show any signs of 'conduction block' or 'asymmetric' slowing that might suggest CIDP instead of CMT?
- • Has a Next-Generation Sequencing (NGS) panel been ordered, and does it cover all the most common CMT genes like PMP22, MFN2, and GJB1?
- • If my genetic test comes back negative, what are the next steps for identifying my specific subtype?
Questions for You
- • Do I have a copy of my Nerve Conduction Study (NCS) and Electromyography (EMG) reports in my personal records?
- • Have I ever experienced a 'fluctuation' in my symptoms—periods where the weakness got much worse over just a few weeks—or has it always been a slow, steady change?
- • Am I currently taking any medications that are known to be 'neurotoxic' (potentially harmful to nerves)?
Want personalized information?
Type your question below to get evidence-based answers tailored to your situation.
References
- 1
Charcot Foot.
Zwipp H, Rammelt S, Dahlen C, Reichmann H
Der Orthopade 1999; (28(6)):550-558 doi:10.1007/PL00003640.
PMID: 28247006 - 2
[Hereditary Polyneuropathies].
Ferbert A, Roth C
Fortschritte der Neurologie-Psychiatrie 2020; (88(3)):198-209 doi:10.1055/a-1009-2270.
PMID: 32232809 - 3
Impact of Customized and Sustained Physiotherapy in Charcot-Marie-Tooth Disease.
Chitapure T, Jethwani D, Zubair Ahmed S, Panigrahy C
Cureus 2021; (13(8)):e17201 doi:10.7759/cureus.17201.
PMID: 34540429 - 4
Cervical radiculopathy for neurologists: the role of electrodiagnosis.
Gonçalves LI, Oliveira Junior PH, Baima JPS
Arquivos de neuro-psiquiatria 2025; (83(10)):1-6 doi:10.1055/s-0045-1812893.
PMID: 41314639 - 5
Novel mutation in the MPZ gene causes early-onset but slow-progressive Charcot-Marie-Tooth disease in a Russian family: a case report.
Kozina AA, Baryshnikova NV, Ilinskaya AY, et al.
The Journal of international medical research 2022; (50(12)):3000605221139718 doi:10.1177/03000605221139718.
PMID: 36567457 - 6
A novel TFG c.793C>G mutation in a Chinese pedigree with Charcot-Marie-Tooth disease 2.
Wu DW, Li Y, Yin X, Zhang B
Brain and behavior 2020; (10(9)):e01724 doi:10.1002/brb3.1724.
PMID: 32666699 - 7
Electrophysiological and radiological diagnosis of hereditary motor and sensory polyneuropathy.
Al-Khlaiwi T, Meo I, Butt MA, Khan A
Journal of family medicine and primary care 2024; (13(6)):2511-2515 doi:10.4103/jfmpc.jfmpc_1513_23.
PMID: 39027825 - 8
[Charcot-Marie-Tooth Disease: Historical Evolution and Present Understanding].
Yano C, Takashima H
Brain and nerve = Shinkei kenkyu no shinpo 2025; (77(11)):1176-1184 doi:10.11477/mf.188160960770111176.
PMID: 41233175 - 9
The Importance of Multiple Gene Analysis for Diagnosis and Differential Diagnosis in Charcot Marie Tooth Disease.
Yalcintepe S, Gurkan H, Dogan IG, et al.
Turkish neurosurgery 2021; (31(6)):888-895 doi:10.5137/1019-5149.JTN.33661-21.3.
PMID: 34169998 - 10
Hereditary neuropathy.
Pisciotta C, Shy ME
Handbook of clinical neurology 2023; (195()):609-617 doi:10.1016/B978-0-323-98818-6.00009-1.
PMID: 37562889 - 11
High diagnostic yield with algorithmic molecular approach on hereditary neuropathies.
Ceylan GG, Habiloğlu E, Çavdarlı B, et al.
Revista da Associacao Medica Brasileira (1992) 2023; (69(2)):233-239 doi:10.1590/1806-9282.20220929.
PMID: 36790232 - 12
[Phenotypes of Charcot-Marie-Tooth Syndrome and Differential Diagnosis Focused in Inflammatory Neuropathies].
Iijima M
Brain and nerve = Shinkei kenkyu no shinpo 2016; (68(1)):31-42 doi:10.11477/mf.1416200343.
PMID: 26764297 - 13
CIDP, CMT1B, or CMT1B plus CIDP?
Cardellini D, Zanette G, Taioli F, et al.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(3)):1127-1130 doi:10.1007/s10072-020-04789-5.
PMID: 33070202 - 14
Repeated clear benefits of immunotherapy in a patient with Charcot-Marie-Tooth disease carrying a rare point mutation in PMP22.
Kawai H, Nishida Y, Kanda T, Yokota T
Neurogenetics 2025; (26(1)):37 doi:10.1007/s10048-025-00808-9.
PMID: 40126701 - 15
A Case Series of Unilateral Peripheral Neuropathy.
Kramarz C, Masingue M, Bouhour F, et al.
Journal of the peripheral nervous system : JPNS 2025; (30(2)):e70033 doi:10.1111/jns.70033.
PMID: 40420622 - 16
Electrodiagnosis: How to Read Electromyography Reports for the Nonneurophysiologist.
Laughlin RS, Rubin DI
Neurologic clinics 2023; (41(1)):45-60 doi:10.1016/j.ncl.2022.05.003.
PMID: 36400558
This page explains diagnostic testing for Charcot-Marie-Tooth disease for educational purposes only. Always consult your neurologist or genetic counselor to interpret your specific electromyography and genetic test results.
Stay up to date
Get notified when new research about Charcot-Marie-Tooth disease/Hereditary motor and sensory neuropathy is published.
No spam. Unsubscribe anytime.